SOHO 2023 Meet-the-Professor Session Details

Meet-the-Professor I

7:00 AM–
7:45 AM

MTP Session I: AML
Chair: Sanam Loghavi

What is New in the WHO Classification of AML?
Sanam Loghavi, MD | MD Anderson Cancer Center, Houston, Texas, USA
What is New in the ICC Classification of AML?
Robert Hasserjian, MD | Massachusetts General Hospital, Boston, Massachusetts, USA
How Do We Reconcile These Classifications in Clinical Management and Research?
Andrew Wei, MBBS, PhD | Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia

MTP Session II: ALL
Chair: Selina Luger

MRD in Ph+ ALL: How Do You Measure It and What Does It Mean?
Nicholas Short, MD | MD Anderson Cancer Center, Houston, Texas, USA
MRD in Ph- ALL: How Should It Be Measured?
Wendy Stock, MD | University of Chicago, Chicago, Illinois, USA
MRD in Ph- ALL: How Should It Direct Treatment?
Nicolas Boissel, MD, PhD | Hôpital Saint-Louis, Université Paris, Paris, France

MTP Session III: Lymphoma 1
Chair: Ann LaCasce

Balancing Risk and Benefit in Limited-Stage Hodgkin Lymphoma
Pamela Allen, MD, MSc | Emory University, Atlanta, Georgia, USA
What is the Role of Allogeneic Transplantation in Hodgkin Lymphoma?
John Kuruvilla, MD, FRCPC | Princess Margaret Cancer Centre, Toronto, Canada
Treatment Approach to AYA Patients With Lymphoma?
Ann LaCasce, MD, MMSc | Dana-Farber Cancer Institute, Boston, Massachusetts, USA

MTP Session IV: Lymphoma 2
Chair: Carla Casulo

Should We Use Prognostic Indices and/or Biomarkers to Guide Therapy in Follicular Lymphoma?
Jessica Okosun, MA, MB BChir, MRCP, FRCPath, PhD | Barts Cancer Institute, London, United Kingdom
What to do in Early Relapse of Follicular Lymphoma
Carla Casulo, MD | University of Rochester Medical Center, Rochester, New York, USA
Integrating Bispecifics into the Clinical Care of Patients With Follicular Lymphoma
Gilles Salles, MD, PhD | Memorial Sloan Kettering, New York, New York, USA

MTP Session V: CML
Chair: Delphine Rea

The Patient With Co-Morbidities: Choosing the Best Drug
Michael J Mauro, MD, PhD | Memorial Sloan Kettering, New York, New York, USA
Reducing TKI Doses Both as a Stepping Stone to TFR and for Long-Term Maintenance
Charlotte Bekker, PhD | Radboud University, Nijmegen, The Netherlands
Should Everyone Meeting Criteria Get Offered TFR – What Do You Do If Monitoring Is Limited
Susanne Saussele, MD | University of Heidelberg, Mannheim, Germany

MTP Session VI: MPN
Chair: Kristen Pettit

Current and Emergent Therapies for Systemic Mastocytosis
Prithviraj Bose, MD | MD Anderson Cancer Center, Houston, Texas, USA
Current and Emergent Therapies for ET
Kristen Pettit, MD | University of Michigan, Ann Arbor, Michigan, USA
Current and Emergent Therapies for PV
Lucia Masarova, MD | MD Anderson Cancer Center, Houston, Texas, USA

MTP Session VII: MDS
Chair: Valeria Santini

Treatment of Lower Risk MDS
Valeria Santini, MD | University of Florence, Florence, Italy
Treatment of Higher Risk MDS
Amy E DeZern, MD, MHS | Johns Hopkins Cancer Center, Baltimore, Maryland, USA
Transplant in MDS
Bart L Scott, MD | Fred Hutchinson Cancer Center, Seattle, Washington, USA

MTP Session VIII: MM
Chair: Meletios Dimopoulos

MGUS / SMM: Incidence, Evaluation, and Follow-up
Natalie S Callander, MD | University of Wisconsin, Madison, Wisconsin, USA
Amyloidosis: Frontline, Salvage and Anti-Fibril Therapy
Suzanne Lentzsch, MD, PhD | Columbia University, New York, New York, USA
Waldenstroms Macro: Novel Agents – Which to Choose
Meletios A Dimopoulos, MD | Alexandra Hospital University of Athens, Athens, Greece

MTP Session IX: CLL
Chair: Jennifer Brown

Covalent BTKi
Jennifer A Woyach, MD | Ohio State University, Columbus, Ohio, USA
Non-Covalent BTKi/Degraders
Krish Patel, MD | Swedish Cancer Institute, Seattle, Washington, USA
Mutations With BTKi
Jennifer R Brown, MD, PhD | Dana-Farber Cancer Institute, Boston, Massachusetts, USA

MTP Session X: CT
Chair: Sergio Giralt
Updates on Hematopoietic Cell Transplantation

Donor Selection in 2023: What is New?
Rohtesh S Mehta, MD, MPH, MS | Fred Hutchinson Cancer Center, Seattle, Washington, USA
GVHD Prevention: What is the New Standard?
Najal El Jurdi, MD | University of Minnesota, Minneapolis, Minnesota, USA
tHCT: Does Graft Composition Matter?
Simone Minnie, PhD | Fred Hutchinson Cancer Center, Seattle, Washington, USA

Meet-the-Professor II

8:00 AM–
8:45 AM

MTP Session XI: AML
Chair: Farhad Ravandi

Update on Molecular Monitoring in AML
Laura Dillon, PhD, FACMG | National Institutes of Health, Bethesda, Maryland, USA
Can Intervention at MRD Stage Improve the Outcomes in AML Subsets?
Richard Dillon, MD | Guys Hospital Trust, London, United Kingdom
Is MRD Assessment Relevant in Low-Intensity Regimens?
Gail J Roboz, MD | Weill Medical College, Cornell Univ, New York, New York, USA

MTP Session XII: ALL
Chair: Kristen O'Dwyer

Novel Agents
Kristen O'Dwyer, MD | University of Rochester Medical Center, Rochester, USA
Early T-Cell
Nitin Jain, MD | MD Anderson Cancer Center, Houston, Texas, USA
CAR-T for R/R T ALL and Lymphoblastic Lymphoma
Maksim Mamonkin, PhD | Baylor College of Medicine, Houston, Texas, USA

MTP Session XIII: Lymphoma 1
Chair: Mark Roschewski

Is There Still a Role for CNS Prophylaxis in Large B-Cell Lymphoma?
Adam J Olszewski, MD | Brown University, Providence, Rhode Island, USA
Circulating Tumor DNA in Lymphoma: When Will This Be Ready for Prime Time?
Mark J Roschewski, MD | NCI Center for Cancer Research, Bethesda, Maryland, USA
Measuring Physical Function and Tolerability on Treatment in Patients With Lymphoma
Gita Thanarajasingam, MD | Mayo Clinic Rochester, Rochester, Minnesota, USA

MTP Session XIV: Lymphoma 2
Chair: Michael Wang
NHL Treatment Options

Mantle Cell Lymphoma
Michael Wang, MD | MD Anderson Cancer Center, Houston, Texas, USA
High-Grade B-Cell Lymphoma
Brian T Hill, MD, PhD | Cleveland Clinic, Cleveland, Ohio, USA
DLBCL in Older Patients
Pallawi Torka, MD | Memorial Sloan Kettering, New York, New York, USA

MTP Session XV: CML
Chair: Delphine Rea

The Patient With Co-Morbidities: Choosing the Best Drug
Michael J Mauro, MD, PhD | Memorial Sloan Kettering, New York, New York, USA
Reducing TKI Doses Both as a Stepping Stone to TFR and for Long-Term Maintenance
Charlotte Bekker, PhD | Radboud University, Nijmegen, The Netherlands
Should Everyone Meeting Criteria Get Offered TFR – What Do You Do If Monitoring Is Limited?
Susanne Saussele, MD | University of Heidelberg, Mannheim, Germany

MTP Session XVI: MPN
Chair: Kristen Pettit

Current and Emergent Therapies for Systemic Mastocytosis
Prithviraj Bose, MD | MD Anderson Cancer Center, Houston, Texas, USA
Current and Emergent Therapies for ET
Kristen Pettit, MD | University of Michigan, Ann Arbor, Michigan, USA
Current and Emergent Therapies for PV
Lucia Masarova, MD | MD Anderson Cancer Center, Houston, Texas, USA

MTP Session XVII: MDS
Chair: Valeria Santini

Treatment of Lower Risk MDS
Valeria Santini, MD | University of Florence, Florence, Italy
Treatment of Higher Risk MDS
Amy E DeZern, MD, MHS | Johns Hopkins Cancer Center, Baltimore, Maryland, USA
Transplant in MDS
Bart L Scott, MD | Fred Hutchinson Cancer Center, Seattle, Washington, USA

MTP Session XVIII: MM
Chair: Meletios Dimopoulos

MGUS / SMM: Incidence, Evaluation, and Follow-up
Natalie S Callander, MD | University of Wisconsin, Madison, Wisconsin, USA
Amyloidosis: Frontline, Salvage and Anti-Fibril Therapy
Suzanne Lentzsch, MD, PhD | Columbia University, New York, New York, USA
Waldenstroms Macro: Novel Agents – Which to Choose
Meletios A Dimopoulos, MD | Alexandra Hospital University of Athens, Athens, Greece

MTP Session XIX: CLL
Chair: Jan Burger

Biology of Richter's
Davide Rossi, MD, PhD | Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
SOC Therapy of Richter's
Deborah M Stephens, DO | University of North Carolina, Chapel Hill, North Carolina, USA
Novel Therapies of Richter's
William Wierda, MD, PhD | MD Anderson Cancer Center, Houston, Texas, USA

MTP Session X: CT
Chair: Sergio Giralt
Updates on Hematopoietic Cell Transplantation

Donor Selection in 2023: What is New?
Rohtesh S Mehta, MD, MPH, MS | Fred Hutchinson Cancer Center, Seattle, Washington, USA
GVHD Prevention: What is the New Standard?
Najal El Jurdi, MD | University of Minnesota, Minneapolis, Minnesota, USA
tHCT: Does Graft Composition Matter?
Simone Minnie, PhD | Fred Hutchinson Cancer Center, Seattle, Washington, USA

MTP Session XX: CT
Chair: Damian Green
Cell Therapy for Myeloma

New Targets/New Product
Ajay K Nooka, MD, MPH, FACP | Winship Cancer Institute, Atlanta, Georgia, USA
Real World Experience With Current Products
Krina K Patel, MD, MSc | MD Anderson Cancer Center, Houston, Texas, USA
CARs vs BITEs for MM
Damian Green, MD | Fred Hutchinson Cancer Center, Seattle, Washington, USA

SOHO 2023 Meet-the-Professor Session Details

Meet-the-Professor I

Meet-the-Professor II

Contact

About the Society